All News

So who with inflamm arthralgias might benefit from abatacept, in terms of delaying RA onset? ALTO study (APIPPRA continuation) 1y abatacept then follow If autoAb x5 (RF, ACPA IgG, IgA, anti-CarP, AAPA): sustained delay of RA If not: benefit only on Rx #ACR25 ABST1678 @RheumNow https://t.co/3Pc5ZLzVf6

Links:

David Liew drdavidliew ( View Tweet)
TNFi induction first year in RA leads to: - less D2T RA at 5y - more sustained remission from 10y onward - less DMARD utilization - less healthcare utilization in these real-world matched cohorts given biosimilar prices, this might be worth considering #ACR25 ABST1677 @RheumNow https://t.co/uL9nHtLkXZ

Links:

David Liew drdavidliew ( View Tweet)
Early TNFi treatment leads to -Less D2T at 5 yrs -More sustained remission at 10yrs -Less bDMARD escalation at 5yrs -More DMARD free remission at 5yrs and 10 yrs -20% reduction annual healths costs -11 mo delay in ttmt escalation Safety data were not presented #ACR25 https://t.co/jPMGUGPtqP

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
SELECT-COMPARE RA UPA vs. ADA What do we learn from 7 years data? Not much Patients who did well on the first drug, keep doing well Patients who required switching for primary failure don't do as well, w/ 26% pts reaching DAS remission in UPA + MTX vs. 16% in ADA + MTX gp No https://t.co/JLUTRZuZOm

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
In case you missed it in @ACR_Journals: HCQ for 1y does not prevent RA development in people with CCP3 >2x ULN, either: - during 1y of treatment - in 2y follow-up https://t.co/gtzNiSmutb but StopRA will give us plenty of insights - data is never wasted #ACR25 ABST1674 @RheumNow https://t.co/DDZib5VGtX

Links:

David Liew drdavidliew ( View Tweet)
SELECT-COMPARE (upadacitinib vs adallimumab in mod-severe RA, no CV enrichment) 7y data: safety profiles very similar, except for: - zoster - CK rise - lymphopenia - hepatic disorder In the general RA population, no new JAKi safety signals #ACR25 ABST1676 @RheumNow https://t.co/BA2JxONGfa

Links:

David Liew drdavidliew ( View Tweet)
Start strong, stay strong. With early anti-TNF induction (vs csDMARD T2T) - At 5 yrs: D2T RA in <1% vs 7% (OR 0.11, p=0.03) Drug-free remission 13% vs 6% (p=0.049) - At 10 yrs: more sustained remission (62% vs 45%) & fewer multi-MoA failures. @RheumNow #ACR25 Abstract #1677

Jiha Lee JihaRheum ( View Tweet)

What is the secret of a VNS RCT that works in RA? => Implant the device! RESET-RA RCT Sham controlled 3mo Then open label in active arm for 66mo 40% pts IR to >=3 bioDMARDs ACR 20 3 mo 42% vs. 19% CDAI LDA 27% vs. 11% 82% TNF IR pt had no change in treatment over 12mo 99% https://t.co/lfxa4YXUB4

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
Implantable vagal stimulator led to benefit in TNF-inadequate responder RA in this sham-controlled double-blind RCT (RESET-RA study) - 82% off b/tsDMARDs at 12mo - also with benefit to control group after crossover at 3mo to an active device #ACR25 1675 @RheumNow https://t.co/yYwWCKm6HF

Links:

David Liew drdavidliew ( View Tweet)
In the SERENA study (n=292), secukinumab reduced PsA incidence to 0.49/100 PY over 5 years in PsO patients with nail involvement, an ~82% drop vs historic non-biologic rates (2.7/100 PY). 98.3% remained PsA-free; PASI 90 achieved in 63%. Abstract#1463 @RheumNow #ACR25 https://t.co/ySOuFJiwge

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Beyond biologics: RA meets bioelectric medicine. In RESET-RA, TNFi inadequate response or intolerant (n=124), vagus nerve stimulation led to significant & durable improvement 🔹 ACR20 3mo: 42% active vs 18% sham (p=0.0057) 🔹 Benefits through 12mo @RheumNow #ACR25 A#1675

Jiha Lee JihaRheum ( View Tweet)

Short chain fatty acids (SCFA) and the relevant microbiome have been linked to RA development and severity. Study of monozygotic twins, where only one has RA, two diff cohorts: lower SCFA lower SCFA microbiome Biomarkers, or even therapeutic target? #ACR25 ABST0442 @RheumNow https://t.co/HW1YfkfOG3

Links:

David Liew drdavidliew ( View Tweet)
Screening for ILD in RA patients: CXR and PFTs by themselves are close to a waste of time. When it comes to screening (high-risk) RA patients, it’s HRCT (or lung USS) or nothing really. (in keeping with EULAR, ACR guidelines) #ACR25 ABST1335 @RheumNow https://t.co/XBDxLwYsAT

Links:

David Liew drdavidliew ( View Tweet)
England et al. Predictors of progression RA-ILD - UIP pattern (HR 1.46), current (HR 1.98) and former (HR 1.60) smoking, age (HR 1.03). @RheumNow #ACR25 Abstr#1308 https://t.co/IvQo8Istta

Links:

Richard Conway RichardPAConway ( View Tweet)
Mease et al. What agent to use after failure of first TNFi in PsA. Real world study, 320 patients. Switching to upadacitinib led to better joint responses than second TNFi or IL17i @RheumNow #ACR25 Abstr#1453 https://t.co/SQnN0skw7r

Links:

Richard Conway RichardPAConway ( View Tweet)
What can we use to better predict MACE in RA patients? ESPOIR cohort showed value of two cardiac biomarkers: - hs-cTnT - soluble ST2 Combined, predicted MACE even after adjusting for disease activity/traditional CV RF. We need something like this! #ACR25 ABST1334 @RheumNow https://t.co/EUNDuuMaYD

Links:

David Liew drdavidliew ( View Tweet)
Loarce et al. Poor performance of CXR and PFT in diagnosing RA-ILD (compared to HRCT). Message is, if you think they have RA-ILD, you need to do CT. @RheumNow #ACR25 Abstr#1335 https://t.co/eeSTf72mvM

Links:

Richard Conway RichardPAConway ( View Tweet)
Getting RA patients into remission: have we plateaued? @MayoClinic data: early and later into the biologic era, and still median time to RA remission is >3y Surely we can aspire to more? Let’s target barriers to implementing better #ACR25 @ElHasbaniG @MyasoedovaElena @RheumNow https://t.co/JLTuL5cIet

Links:

David Liew drdavidliew ( View Tweet)
Pope @Janetbirdope et al. Parenteral (IM and/or IA) superior to oral steroids in early RA. Better discontinuation of steroids with no difference in need for advanced therapies. @RheumNow #ACR25 Abstr#1355 #ACRbest https://t.co/OyvnzEGlLE

Links:

Richard Conway RichardPAConway ( View Tweet)
After At-risk RA, time to discuss At-risk PsA patients ARP-PsA Prospective cohort 1400+ pts 8.4% met ARP-PsA criteria (arthralgia + Fam Hx +Pso, not referred via Dermatology) Risk factors: Pso >15 years Pso + Family Hx US synovitis/enthesitis At 1 yr follow-up 30% progressed https://t.co/ZY2ezh8nZN

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×